Skip to main content
Contact Us
Subscribe
E-Edition
85°
Site search
Search
Menu
Open user controls
Log In Using Your Account
Log In
Don't have an account?
Sign Up Today
My Account
Dashboard
Profile
Saved items
Logout
Home
About Us
Contact Us
Advertise
Terms and Conditions
Privacy Policy
Home Delivery
Subscription Services
Place an Ad
Promote Your Event
Local Weather
News
Sports
Obits
Multimedia
Photo Galleries
Videos
e-Edition
Classifieds
Real Estate
Property For Rent
Cars & Vehicles
Jobs
Items For Sale
Pets
Auctions, Estate & Garage Sales
Services
Community
Personals
Place An Ad
Subscribe
Best of 2024
Archives
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude Oil
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries
Rallybio Corporaton
(NQ:
RLYB
)
1.150
-0.040 (-3.36%)
Streaming Delayed Price
Updated: 4:00 PM EDT, Aug 30, 2024
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
Press Releases about Rallybio Corporaton
< Previous
1
2
3
Next >
Rallybio Reports First Quarter 2023 Financial Results
May 09, 2023
From
Rallybio Corporation
Via
Business Wire
Rallybio to Present at the JMP Securities 2023 Life Sciences Conference
May 08, 2023
From
Rallybio Corporation
Via
Business Wire
Rallybio Announces Clinical Proof-of-Concept Results for RLYB211, an Anti-HPA-1a Polyclonal Antibody for the Prevention of Fetal and Neonatal Alloimmune Thrombocytopenia (FNAIT), Published in the Journal of Thrombosis and Haemostasis
April 06, 2023
From
Rallybio Corporation
Via
Business Wire
Rallybio Announces Acceptance of Abstract for RLYB212 at the 31st Congress of the International Society on Thrombosis and Haemostasis (ISTH)
April 03, 2023
From
Rallybio Corporation
Via
Business Wire
Rallybio Reports Fourth Quarter and Full Year 2022 Financial Results
March 06, 2023
From
Rallybio Corporation
Via
Business Wire
Rallybio Announces Proof-of-Concept Achieved for RLYB212, a Novel Monoclonal anti-HPA-1a Antibody to Prevent Fetal and Neonatal Alloimmune Thrombocytopenia
March 06, 2023
From
Rallybio Corporation
Via
Business Wire
Rallybio to Present at Upcoming Investor Conferences in March
March 01, 2023
From
Rallybio Corporation
Via
Business Wire
EyePoint and Rallybio Announce Research Collaboration to Evaluate Rallybio’s Inhibitor of Complement Component 5 (C5) and EyePoint’s Proprietary Durasert® Technology for Sustained Intraocular Delivery in Geographic Atrophy
February 27, 2023
From
Rallybio Corporation
Via
Business Wire
Rallybio Announces Appointment of Jonathan I. Lieber as Chief Financial Officer
January 31, 2023
From
Rallybio Corporation
Via
Business Wire
Rallybio Highlights Portfolio Advances and Outlines Expected Milestones in 2023
January 05, 2023
From
Rallybio Corporation
Via
Business Wire
Rallybio Announces Publication of Data Highlighting the Ability of HPA-1a-Specific Antibodies to Prevent Alloimmunization in an Authentic Mouse Model of FNAIT
December 15, 2022
From
Rallybio Corporation
Via
Business Wire
AbCellera and Rallybio Announce Strategic Alliance to Discover, Develop, and Commercialize Novel Antibody-Based Therapeutics for Rare Diseases
December 01, 2022
From
Rallybio Corporation
Via
Business Wire
Rallybio to Present at the JMP Securities Hematology and Oncology Summit
November 29, 2022
From
Rallybio Corporation
Via
Business Wire
Rallybio to Present at Upcoming Investor Conferences in November
November 11, 2022
From
Rallybio Corporation
Via
Business Wire
Rallybio Announces Pricing of $50 Million Public Offering
November 10, 2022
From
Rallybio
Via
Business Wire
Rallybio Announces Proposed Public Offering
November 10, 2022
From
Rallybio Corporation
Via
Business Wire
Rallybio Reports Third Quarter 2022 Financial Results
November 07, 2022
From
Rallybio Corporation
Via
Business Wire
Rallybio Announces Positive Phase 1 Single Ascending Dose Results for RLYB116, an Innovative Subcutaneously Injected Inhibitor of Complement Component 5
November 07, 2022
From
Rallybio Corporation
Via
Business Wire
Rallybio Announces Positive Preliminary Results for RLYB212, an anti-HPA-1a Monoclonal Antibody for the Prevention of Fetal and Neonatal Alloimmune Thrombocytopenia
September 28, 2022
From
Rallybio Corporation
Via
Business Wire
Rallybio to Present at the 2022 Wells Fargo Healthcare Conference
August 31, 2022
From
Rallybio Corporation
Via
Business Wire
Rallybio Reports Second Quarter 2022 Financial Results
August 08, 2022
From
Rallybio Corporation
Via
Business Wire
Rallybio Appoints Wendy K. Chung, M.D., Ph.D., to Its Board of Directors
August 02, 2022
From
Rallybio Corporation
Via
Business Wire
Rallybio Announces Retirement of Jeffrey Fryer, CPA, Chief Financial Officer
June 02, 2022
From
Rallybio Corporation
Via
Business Wire
Rallybio to Present at Upcoming Investor Conferences in June
June 01, 2022
From
Rallybio Corporation
Via
Business Wire
Rallybio Reports First Quarter 2022 Financial Results
May 10, 2022
From
Rallybio Corporation
Via
Business Wire
Rallybio Announces In-Licensing of Potential First-In-Class Preclinical Antibody Candidate from Sanofi
May 10, 2022
From
Rallybio Corporation
Via
Business Wire
Rallybio Appoints Christine A. Nash and Hui Liu, Ph.D., to Its Board of Directors
April 04, 2022
From
Rallybio Corporation
Via
Business Wire
Rallybio Reports Fourth Quarter and Full Year 2021 Financial Results
March 15, 2022
From
Rallybio Corporation
Via
Business Wire
Rallybio to Present at the Cowen 42nd Annual Health Care Conference
February 28, 2022
From
Rallybio Corporation
Via
Business Wire
Ami Bavishi Joins Rallybio to Lead Investor Relations and Corporate Communications
January 18, 2022
From
Rallybio Corporation
Via
Business Wire
< Previous
1
2
3
Next >
Data & News supplied by
www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms and Conditions
.